A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence. This study aims to analyze and compare adverse drug r...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2025-04-01
|
| Sarja: | Frontiers in Pharmacology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1561020/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|